Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead gets rights to Ono's oral BTK inhibitor

Executive Summary

Ono Pharmaceutical Co. Ltd. granted Gilead Sciences Inc. exclusive rights to co-develop and sell ONO4059, an oral Bruton’s tyrosine kinase (BTK) inhibitor. Gilead can commercialize the compound worldwide, excluding Japan, South Korea, Taiwan, China, and the Association of Southeast Asian Nations (ASEAN), where Ono retains rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies